Tissue Regenix to acquire CellRight Technologies

Tissue Regenix has agreed to acquire CellRight Technologies, a US-based regenerative medicine business that specialises in human tissue and soft tissue products for clinical applications in spine, dental, sports medicine and general surgery. The deal, worth up to £23m, will be funded through the placing of 400m shares with both new and existing institutional investors, which will raise £40m. The money left over will be invested in the company’s objective of achieving profitability by 2020.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.